Silexion Therapeutics Corp Dossier
Qualitative Analysis
Business overview
Silexion Therapeutics Corp (NASDAQ: SLXN) is a clinical-stage, oncology-focused biotechnology company specializing in the discovery and development of innovative RNA interference (RNAi) therapies for KRAS-driven cancers. The company's proprietary platform utilizes chemically modified small interfering RNA (siRNA) constructs encapsulated in extended-release poly(lactic-co-glycolic acid) (PLG) microparticles. This design is engineered to prompt tumor cells to degrade the messenger RNA (mRNA) bridging oncogenes and cellular protein synthesis machinery, thereby silencing mutated KRAS at the genetic level. Silexion's lead product candidate, SIL204, is a second-generation siRNA therapeutic designed to target a broad spectrum of clinically relevant KRAS mutations (including G12D and G12V). It is administered locally via standard endoscopy directly into solid tumors, slowly releasing the therapeutic payload over an extended period of 2 to 3 months.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Advancing the next-generation siRNA candidate SIL204 using an innovative dual-route administration strategy that combines intratumoral delivery (to target primary tumors) with systemic administration (to address metastatic disease) in KRAS-driven cancers.
Expected impact: Aims to provide a highly effective therapeutic option for locally advanced pancreatic cancer (LAPC) by silencing mutated KRAS oncogenes.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
To complete a business combination resulting in Silexion Therapeutics Corp becoming a publicly-traded holding company listed on the Nasdaq Capital Market under the ticker SLXN.
Financial impact: Provided Silexion with a public listing platform and initial capital, though subsequent capital raises and reverse splits were executed to maintain listing compliance.
Strategic Partnerships
Catalent conducts formulation development and GMP clinical manufacturing of SIL204 at its facility in Limoges, France, optimizing both systemic and intratumoral delivery formulations.
Terms: Terms not publicly disclosed.
AMS was selected to manage and support the regulatory strategy, clinical trial design, site selection, and data analysis for Silexion's Phase 2/3 clinical trial of SIL204.
Terms: Terms not publicly disclosed.
Collaborating on advanced siRNA formulation technologies to enhance the delivery and therapeutic efficacy of Silexion's RNAi candidates.
Terms: Terms not publicly disclosed.